I didn't see it on clinicaltrials.gov this morning either. In today's news release, it read:

"Primary outcome measures will be time to first occurrence of MACE as defined above. Secondary outcome measures and additional trial details and updates can be found at: www.clinicaltrials.gov and/or www.clinicaltrialsregister.eu/."

"Resverlogix has received initial approval from the regulatory authority and ethics committee in the first three countries: Belgium, Hungary and Israel, which will represent approximately 15 investigative sites of an expected 175 site trial. The first site initiation visit was held today and with drug now available to the centers, enrollment of patients will commence. Over the course of the coming months, additional investigative sites will be activated."

Perhaps when other sites are activated, we will see BETonMACE listed on clinicaltrial.gov as well. I recall Argentina, Australia, and of course some Chinese territories being mentioned in addition to the European sites. So perhap when those sites not regulated by the EU are activated, it will appear on ClinicalTrials.gov? That's my guess.

Great news today nonetheless!

BearDownAZ